Showing results (41-50 of 49) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 2008
Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonistMarc Iglarz, Christoph Binkert, Keith Morrison, et al.Journal of Medicinal Chemistry|August 7, 2012
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonistMartin H Bolli, Christoph Boss, Christoph Binkert, et al.Journal of Medicinal Chemistry|May 14, 2004
Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonistsMartin H Bolli, Judith Marfurt, Corinna Grisostomi, et al.Bioorganic & Medicinal Chemistry Letters|January 23, 2014
Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1Thierry Sifferlen, Amandine Boller, Audrey Chardonneau, et al.Chemmedchem|August 23, 2014
Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonistChristoph Boss, Catherine Roch-Brisbare, Michel A Steiner, et al.Bioorganic & Medicinal Chemistry Letters|October 27, 2009
New classes of potent and bioavailable human renin inhibitorsL'ubos Remen, Olivier Bezençon, Sylvia Richard-Bildstein, et al.Journal of Medicinal Chemistry|April 11, 2009
Design and preparation of potent, nonpeptidic, bioavailable renin inhibitorsOlivier Bezençon, Daniel Bur, Thomas Weller, et al.Journal of Medicinal Chemistry|November 26, 2013
Novel S1P1 receptor agonists--part 1: From pyrazoles to thiophenesMartin H Bolli, Claus Müller, Boris Mathys, et al.Journal of Medicinal Chemistry|May 8, 2010
2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonistsMartin H Bolli, Stefan Abele, Christoph Binkert, et al.Pageof 5